BioCentury | Mar 17, 2017
Company News

Shionogi, Duchesnay deal

...severe dyspareunia due to postmenopausal vulvovaginal atrophy. Shionogi has exclusive, worldwide rights to Osphena from QuatRx Pharmaceuticals Co....
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Thyroid hormone receptor

...to treat hypercholesterolemia and preclinical testing to treat fatty liver disease and non-alcoholic steatohepatitis (NASH). QuatRx Pharmaceuticals Co....
BioCentury | Dec 14, 2015
Clinical News

Ospemifene: Phase III started

...menopause. Shionogi has exclusive, worldwide rights, excluding undisclosed Baltic and Nordic territories, to Osphena from QuatRx...
...HSE:ORNBV, Espoo, Finland) has an option to license rights in undisclosed Baltic and Nordic territories. QuatRx Pharmaceuticals Co....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Imbruvica ibrutinib Relapsed or refractory mantle cell lymphoma (MCL) U.S. (approved in EU 2014) $307.3 QuatRx Pharmaceuticals Co./Shionogi...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

...slated for 2015. Forendo purchased the once-daily orally administered selective estrogen receptor modulator (SERM) from QuatRx Pharmaceuticals Co....
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

...company acquired a portfolio of HSD17B1 inhibitors last year from the Hormos Medical subsidiary of QuatRx Pharmaceuticals Co....
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...Inc. (NASDAQ:PCYC)/Johnson & Johnson (NYSE:JNJ) Imbruvica ibrutinib Relapsed or refractory mantle cell lymphoma (MCL) U.S. QuatRx Pharmaceuticals Co./Shionogi...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

...inhibitors in June from QuatRx Pharmaceuticals Co. 's Hormos Medical subsidiary. Lammintausta was CEO of Hormos when QuatRx...
...2005. He told BioCentury that despite promising preclinical data, the HSD17B1 program was deprioritized at QuatRx...
...the series A money to last through Phase IIa testing. Forendo also purchased fispemifene from QuatRx...
BioCentury | May 13, 2013
Company News

Shionogi sales and marketing update

...Europe. Shionogi has exclusive, worldwide rights, excluding undisclosed Baltic and Nordic territories, to Osphena from QuatRx Pharmaceuticals Co....
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) QuatRx Pharmaceuticals Co./Shionogi...
Items per page:
1 - 10 of 88
BioCentury | Mar 17, 2017
Company News

Shionogi, Duchesnay deal

...severe dyspareunia due to postmenopausal vulvovaginal atrophy. Shionogi has exclusive, worldwide rights to Osphena from QuatRx Pharmaceuticals Co....
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Thyroid hormone receptor

...to treat hypercholesterolemia and preclinical testing to treat fatty liver disease and non-alcoholic steatohepatitis (NASH). QuatRx Pharmaceuticals Co....
BioCentury | Dec 14, 2015
Clinical News

Ospemifene: Phase III started

...menopause. Shionogi has exclusive, worldwide rights, excluding undisclosed Baltic and Nordic territories, to Osphena from QuatRx...
...HSE:ORNBV, Espoo, Finland) has an option to license rights in undisclosed Baltic and Nordic territories. QuatRx Pharmaceuticals Co....
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Imbruvica ibrutinib Relapsed or refractory mantle cell lymphoma (MCL) U.S. (approved in EU 2014) $307.3 QuatRx Pharmaceuticals Co./Shionogi...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

...slated for 2015. Forendo purchased the once-daily orally administered selective estrogen receptor modulator (SERM) from QuatRx Pharmaceuticals Co....
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

...company acquired a portfolio of HSD17B1 inhibitors last year from the Hormos Medical subsidiary of QuatRx Pharmaceuticals Co....
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...Inc. (NASDAQ:PCYC)/Johnson & Johnson (NYSE:JNJ) Imbruvica ibrutinib Relapsed or refractory mantle cell lymphoma (MCL) U.S. QuatRx Pharmaceuticals Co./Shionogi...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

...inhibitors in June from QuatRx Pharmaceuticals Co. 's Hormos Medical subsidiary. Lammintausta was CEO of Hormos when QuatRx...
...2005. He told BioCentury that despite promising preclinical data, the HSD17B1 program was deprioritized at QuatRx...
...the series A money to last through Phase IIa testing. Forendo also purchased fispemifene from QuatRx...
BioCentury | May 13, 2013
Company News

Shionogi sales and marketing update

...Europe. Shionogi has exclusive, worldwide rights, excluding undisclosed Baltic and Nordic territories, to Osphena from QuatRx Pharmaceuticals Co....
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) QuatRx Pharmaceuticals Co./Shionogi...
Items per page:
1 - 10 of 88